目的探讨胸腔镜与开胸肺叶切除术对非小细胞肺癌患者炎症因子及免疫功能的影响。方法选择72例非小细胞肺癌患者为研究对象,根据手术方式不同分为了腔镜组和开胸组。腔镜组在全胸腔镜下行肺叶切除术治疗,开胸组患者接受开胸肺叶切除术治疗。对比两组术中出血量、手术时间、切口长度、淋巴结清扫数目及血清IL-6、C反应蛋白及免疫功能指标等情况。结果腔镜组手术时间、术中出血量均明显少于开胸组,切口长度明显小于开胸组,淋巴结清扫数量多于开胸组(P<0.05)。与术前相比,手术后1 d、5 d两组IL-6、CRP水平都有较为明显的提升,且开胸组明显高于腔镜组;与术后1 d相比,两组术后5 d的IL-6、CRP水平均显著降低(P<0.05)。与术前相比,术后两组IgG、CD4+、CD8+T淋巴细胞水平及CD4+/CD8+水平均明显下降,且开胸组明显低于腔镜组,差异均有统计学意义(P<0.05)。结论全胸腔镜下肺叶切除术治疗非小细胞肺癌效果显著,可明显减轻患者的炎症反应,并在一定程度上帮助机体免疫功能的快速恢复,值得在临床上推广应用。
ObjectiveTo investigate the effects of thoracoscopic and open lobectomy on inflammatory factors and immune function in the patients with non small cell lung cancer. MethodsSeventy-two patients with non small cell lung cancer were selected, and were divided into thoracoscope group and open group according to the operative methods. The thoracoscope group and the open group were treated with thoracoscopic and open lobectomy respectively. The related indices were compared between the two groups, including intraoperative blood loss, operation duration, incision length, number of removed lymph nodes, serum IL-6 level, C reactive protein level and immune function. ResultsCompared to the open group, the operation duration, intraoperative blood loss and incision length were less or shorter, but the number of removed lymph nodes was more in the thoracoscope group (P<0.05). In both groups, the levels of IL-6 and CRP at 1d and 5 d after operation were higher than preoperative levels (P<0.05). The levels of IL-6 and CRP at 1 d and 5 d in the open group were significantly higher than those in the thoracoscope group (P<0.05).In both groups, the levels of IL-6 and CRP at 5 d after operation were lower than the levels at 1 d after operation(P<0.05). In both groups, the levels of IgG, CD4+ and CD8+T lymphocytes, and CD4+/CD8+ after operation were lower than the preoperative levels (P<0.05). The levels of IgG, CD4+ and CD8+T lymphocytes, and CD4+/CD8+ were lower in the thoracoscope group compared to the open group(P<0.05). ConclusionFull thoracoscopic lobectomy is obviously effective for non small cell lung cancer, can alleviate the inflammatory response of the patients and is beneficial to the rapid recovery of immune function to some extent. This approach is worthy of clinical promotion and application.